Aktie A0YH9L AVEO PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen AVEO Pharmaceuticals, Inc. Börse Stuttgart

Aktien

A0YH9L

US0535881090

VPA

Verzögert Börse Stuttgart
Andere Börsenplätze
 16:33:53 05.10.2021 		% 5 Tage % 1. Jan.
5.28 EUR -0.19% Intraday Chart für AVEO Pharmaceuticals, Inc. -10.02% +20.93%
13.06. LG Chem Company und AVEO Oncology geben bekannt, dass LG Chem's erster proprietärer Antikrebswirkstoff in die klinische Studie der Phase 1 eintritt und die Dosierung in den USA begonnen hat CI
25.03. AVEO Pharmaceuticals, Inc. kündigt Veränderungen in der Geschäftsführung an CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
LG Chem Company and AVEO Oncology Announce LG Chem's First Proprietary Anti-Cancer Compound Enters Phase 1 Clinical Study, Dosing Initiated in the U.S
AVEO Pharmaceuticals, Inc. Announces Executive Changes
Aveo Oncology Announces Publication of Long-Term Survival in Patients with Relapsed/Refractory Advanced Renal Cell Carcinoma Treated with Tivozanib: Analysis of the Phase Iii Tivo-3 Trial in the Oncologist
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA(R) in Combination with OPDIVO(R) in Advanced Renal Cell Carcinoma
South Korean Stocks Climb on Demand Recovery Hopes from China; LG Chem Stocks Add 1%
AVEO Completes Acquisition by LG Chem
LG Chem Acquires US Biopharma Firm AVEO Pharmaceuticals
AVEO PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
LG Chem Completes Acquisition of AVEO Oncology
AVEO Pharmaceuticals, Inc. Announces Management Changes
AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from NASDAQ Composite Index
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index
AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P TMI Index
LG Chem, Ltd. completed the acquisition of AVEO Pharmaceuticals, Inc. from a group of shareholders.
AVEO Pharmaceuticals Receives CFIUS Clearance for LG Chem Merger
AVEO Pharmaceuticals : Merger Agreement - Form 8-K
AVEO PHARMACEUTICALS, INC. : Other Events (form 8-K)
AVEO Pharmaceuticals Stockholders Approve LG Chem Merger
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2P0CL Aktie
  4. A0YH9L Aktie
  5. Nachrichten AVEO Pharmaceuticals, Inc.
  6. Andere Sprachen